BMS 188797

Drug Profile

BMS 188797

Alternative Names: BMS-188797

Latest Information Update: 15 Jan 2008

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antineoplastics; Paclitaxels; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 27 May 2004 A study has been added to the Cancer therapeutic trials section
  • 10 Oct 2002 A study has been added to the adverse events and Cancer therapeutic trials sections
  • 25 Jan 2001 A phase I study has been added to the Cancer adverse events and pharmacokinetic sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top